Orchestra BioMed Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Orchestra BioMed Holdings, Inc. (OBIO) on July 30, 2024, reporting events occurring on July 29, 2024. The company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The Board of Directors increased the size of the Board from seven to eight directors. John Mack was appointed as a Class I director, effective immediately, with a term expiring at the 2027 annual meeting of stockholders. Mr. Mack was also appointed to the Audit Committee.
Management Commentary and Governance
- Director Background: Mr. Mack, 60, most recently served as President of Cardiac Surgery for Medtronic, Inc. (2020-2023). He holds a B.S. in business from the University of Minnesota.
- Compensation: Mr. Mack will receive compensation for non-employee directors as described in the Company's 2023 Annual Report on Form 10-K.
- Agreements: Mr. Mack has entered into the Company's standard form indemnification agreement.
- Relationships: The filing states there are no family relationships between Mr. Mack and other directors or officers, and no reportable transactions under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the specific compensation amounts for non-employee directors in the Company's 2023 Form 10-K.
- Review the press release dated July 30, 2024 (Exhibit 99.1) for additional context on the appointment.
- Confirm the updated Board composition and Audit Committee membership in subsequent filings.